Literature DB >> 8951191

Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay.

P Teja-Isavadharm1, F Nosten, D E Kyle, C Luxemburger, F Ter Kuile, J O Peggins, T G Brewer, N J White.   

Abstract

1. The pharmacokinetic and effect kinetic properties of oral (p.o.), intramuscular (i.m.), and intrarectal (i.r.) artemether (5 mg kg-1) were compared in a crossover study in eight healthy adult volunteers. Plasma concentrations of artemether (AM) and its active metabolite dihydroartemisinin (DHA) were measured by high performance liquid chromatography with reductive mode electrochemical detection (h.p.l.c.-ECD), and plasma antimalarial activity in vitro (effect) was assessed on the same samples by a sensitive bioassay (BA). 2. Artemether was absorbed rapidly after oral administration with a mean (95% CI) Cmax for the parent compound of 406 (249 to 561) nmol l-1 and for DHA of 1009 (639 to 1379) nmol l-1 with tmax values of 1.7 (1.2 to 2.2) and 1.8 (1.4 to 2.2) h respectively. The mean (95% CI) elimination half-life of AM was 2.6 (1.8 to 3.4) h and for DHA was 1.9 (1.4 to 2.4) h. Plasma concentration and effect profiles with h.p.l.c.-ECD and BA were similar suggesting that other unidentified bioactive metabolites contributed little to antimalarial activity in vivo. 3. Absorption was slower, more variable, and DHA concentrations were lower following the i.m. and i.r. routes of administration. The mean (95% CI) relative bioavailability compared with oral artemether in the 6 h following administration AUC (0.6h) was 25 (9 to 41)% following i.m. and 35 (10 to 60)% following i.r. artemether. 4. These data demonstrate that oral artemether undergoes extensive first pass metabolism to the more active metabolite DHA. Plasma antimalarial activity following oral administration is significantly greater than following i.m. administration. The i.r. route of administration provided similar bioavailability to i.m. injection but there was considerable variability in absorption following both routes. Further studies are needed to determine whether i.r. artemether would be an effective treatment of severe malaria in the rural tropics in situations where oral or parenteral administration is not possible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951191     DOI: 10.1111/j.1365-2125.1996.tb00115.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

Review 1.  The evolution of drug-resistant malaria: the role of drug elimination half-life.

Authors:  Ian M Hastings; William M Watkins; Nicholas J White
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

2.  The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.

Authors:  Rose McGready; Kasia Stepniewska; Niklas Lindegardh; Elizabeth A Ashley; Yar La; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2006-10-20       Impact factor: 2.953

3.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

Review 4.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 6.  Safety assessment of peroxide antimalarials: clinical and chemical perspectives.

Authors:  B K Park; P M O'Neill; J L Maggs; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

7.  Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.

Authors:  Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

8.  Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.

Authors:  Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors:  N J White; M van Vugt; F Ezzet
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

10.  The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects.

Authors:  M A van Agtmael; C A Van Der Graaf; T K Dien; R P Koopmans; C J van Boxtel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.